CG Oncology Updates on Clinical Trials and Q3 Financial Results
CG Oncology reported $984.5M in cash and updated business milestones for 2026. The company expects to achieve key interim data in its pivotal trials and total $984.5M in cash sufficient to fund operations through 2029.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed